PSMA radioligand therapy of prostate cancer.

PSMA radioligand therapy of prostate cancer. Q J Nucl Med Mol Imaging. 2019 Jan 15;: Authors: Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM Abstract Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate- specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic researche centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targeted β- or α-radiation therapy. PMID: 30644306 [PubMed - as supplied by publisher]
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research